BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

822.74M

Vuru Grade

31.00/100

Current Price

$11.35
-0.045 (-0.395%)

Stability Price

$0.22
Overvalued by 98.09%

Company Metrics

  • 0 P/E
  • 48.657 P/S
  • 12.827 P/B
  • -0.718 EPS
  • -229.93% Cash ROIC
  • 1.26 Cash Ratio
  • 0 / 0% Dividend
  • 909,052.00 Avg. Vol.
  • 72.52M Shares
  • 822.74M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Insider Trade: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Senior Vice ...
OctaFinance.com - May 20, 2015
Thomas Staab is the Senior Vice President and CFO of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 11.39 +0.23 2.06% .
BioCryst Pharmaceuticals CFO Sells $33000.00 in Stock (BCRX) - Dakota Financial News
BioCryst Pharmaceuticals CFO Thomas R. Staab II Sells 3000 Shares (BCRX) - The Legacy
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
Motley Fool - Apr 1, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
Durham's BioCryst gets $35M federal contract for Ebola treatment - Triangle Business Journal
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4% - Zacks.com
Stock Analysis on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Apr 9, 2015
[Globe Newswire] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)(TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's development programs at the 14th Annual Needham ...
BioCryst Pharmaceuticals Receives $16.12 Consensus Target Price from ... - Mideast Time
BofA: We're Upgrading Biocryst Pharmaceuticals
Benzinga - Apr 20, 2015
In a report published Monday, analysts at Bank of America upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) to Neutral.
BioCryst Pharmaceuticals Upgraded to "Neutral" at Bank of America (BCRX) - Dakota Financial News
Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
wsnewspublishers - Mar 24, 2015
On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
Yarlagadda S. Babu Sells 12105 Shares of BioCryst Pharmaceuticals Stock ... - WKRB News
Investors Dumping 4 Biotech Stocks - Intrexon (XON), Idera Pharmaceuticals ... - Wall Street Observer
Buzz Stocks: Charter Communications, Inc., BioCryst Pharmaceuticals, Inc., and ...
Schaeffers Research (blog) - Mar 31, 2015
U.S. benchmarks are poised to pare a portion of yesterday's massive gains, with futures pointed lower on the last day of the first quarter.
Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 29, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
TheStreet.com - Apr 2, 2015
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
BioCryst Pharmaceuticals PT Set at $15.00 by Needham & Company LLC (BCRX) - Dakota Financial News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a Buy: Needham
Markets.co - Apr 6, 2015
In a research note issued to investors, Serge Belanger at Needham Reiterated their Buy rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The analyst placed a $15.00 price target on the stock which indicates a 53.69% upside to the last closing ...
Where is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Headed?
Inside Trade - Dec 23, 2014
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.